Oxford BioMedica PLC said Peter Nolan plans to retire as chief business officer and director of the gene and cell therapy company, effective July 1.
Nolan, who had worked with Oxford BioMedica for over 20 years, will work as a consultant to the company following his retirement.
U.K.-based Oxford BioMedica is involved in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and eye conditions.
